Compare Dishman Pharma with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUVEN LIFE SCIENCES - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUVEN LIFE SCIENCES DISHMAN PHARMA/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 25.1 -86.3 - View Chart
P/BV x 3.3 1.4 247.2% View Chart
Dividend Yield % 0.7 1.7 39.2%  

Financials

 DISHMAN PHARMA   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUVEN LIFE SCIENCES
Mar-19
DISHMAN PHARMA/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs374338 110.9%   
Low Rs129169 76.1%   
Sales per share (Unadj.) Rs197.852.1 379.4%  
Earnings per share (Unadj.) Rs21.26.8 310.4%  
Cash flow per share (Unadj.) Rs34.78.6 405.1%  
Dividends per share (Unadj.) Rs2.001.50 133.3%  
Dividend yield (eoy) %0.80.6 134.3%  
Book value per share (Unadj.) Rs179.965.3 275.5%  
Shares outstanding (eoy) m80.69127.28 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.9 26.2%   
Avg P/E ratio x11.937.1 32.0%  
P/CF ratio (eoy) x7.229.6 24.5%  
Price / Book Value ratio x1.43.9 36.0%  
Dividend payout %9.422.0 42.9%   
Avg Mkt Cap Rs m20,30632,272 62.9%   
No. of employees `0000.81.1 76.6%   
Total wages/salary Rs m5,355661 809.9%   
Avg. sales/employee Rs Th19,252.76,132.2 314.0%   
Avg. wages/employee Rs Th6,459.5611.1 1,057.0%   
Avg. net profit/employee Rs Th2,064.1803.5 256.9%   
INCOME DATA
Net Sales Rs m15,9616,635 240.6%  
Other income Rs m265242 109.5%   
Total revenues Rs m16,2266,877 235.9%   
Gross profit Rs m4,1031,604 255.8%  
Depreciation Rs m1,091221 492.6%   
Interest Rs m94438 2,505.0%   
Profit before tax Rs m2,3341,587 147.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624718 86.9%   
Profit after tax Rs m1,711869 196.8%  
Gross profit margin %25.724.2 106.3%  
Effective tax rate %26.745.2 59.1%   
Net profit margin %10.713.1 81.8%  
BALANCE SHEET DATA
Current assets Rs m11,0186,232 176.8%   
Current liabilities Rs m9,5171,490 638.7%   
Net working cap to sales %9.471.5 13.2%  
Current ratio x1.24.2 27.7%  
Inventory Days Days11086 127.8%  
Debtors Days Days3583 42.2%  
Net fixed assets Rs m16,3044,043 403.2%   
Share capital Rs m161127 126.8%   
"Free" reserves Rs m12,9078,183 157.7%   
Net worth Rs m14,5168,310 174.7%   
Long term debt Rs m4,18918 23,536.0%   
Total assets Rs m29,80510,389 286.9%  
Interest coverage x3.543.1 8.1%   
Debt to equity ratio x0.30 13,474.0%  
Sales to assets ratio x0.50.6 83.8%   
Return on assets %8.98.7 102.0%  
Return on equity %11.810.5 112.7%  
Return on capital %17.519.5 89.8%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9525,622 88.1%   
Fx outflow Rs m6971,799 38.7%   
Net fx Rs m4,2553,822 111.3%   
CASH FLOW
From Operations Rs m2,786356 783.8%  
From Investments Rs m-1,529-279 548.8%  
From Financial Activity Rs m-941-225 418.1%  
Net Cashflow Rs m316-148 -213.5%  

Share Holding

Indian Promoters % 61.4 63.4 96.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 36.5 60.5%  
Shareholders   46,261 37,287 124.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - LUPIN COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS